Acceleron Pharma (XLRN) Tops Q3 EPS by 10c

Acceleron Pharma (NASDAQ: XLRN) reported Q3 EPS of ($0.36), $0.10 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $4.16 million versus the consensus estimate of $4.38 million.

For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Investing.com’s stocks of the week
• Carvana (CVNA) PT Lowered to $85 at RBC Capital